G Protein-Coupled Receptors: Structural Dynamics and Functional Implications

This meeting will focus on how an integration of structural data and information from experiments that study molecular dynamics in vitro, in vivo and in silico can be integrated to form an in-depth view of GPCR function. In addition, key therapeutic areas of cancer, inflammation and disorders of the central nervous system will be highlighted in relation to the development of novel therapeutics targeting GPCRs.
+ show speakers and program
Sunday, March 30
Arrival and Registration

Monday, March 31
Keynote Address (Joint): Robert J. Lefkowitz, HHMI/Duke University Medical Center, USA

AM Plenary: Cutting-Edge Biophysics to Study Membrane Protein Conformational Changes (Joint)
Petra Fromme, Arizona State University, USA
Femtosecond Nanocrystallography of Membrane Proteins
Martin J. Lohse, Universität Würzburg, Germany
Studying GPCR Conformational Changes Using Fluorescence-Based Assays in Living Cells
Ron O. Dror, D. E. Shaw Research, USA
Revealing Structural Dynamics of GPCR Signaling through Atomic-Level Simulation Wayne L. Hubbell, University of California, Los Angeles, USA
Conformational Dynamics of GPCRs Studied by Site-Directed Spin Labeling

PM Plenary: Family C and Frizzled GPCRs
Jean-Philippe Pin, Institute of Functional Genomics, Montpellier University, France
Metabotropic Glutamate Receptors Robert Lütjens, Addex Therapeutics, Switzerland
Discovery of Allosteric Modulators of Metabotropic Glutamate Receptors
Gunnar Schulte, Karolinska Institutet, Sweden
New Insights into Frizzled Signaling through Heterotrimeric G Proteins
Short Talk Chosen from Abstracts

AM Plenary: Family B GPCRs
Kaspar Hollenstein, Heptares Therapeutics, UK
Structure of a Family B GPCR: CRF1
Patrick M. Sexton, Monash University, Australia
GLP1 Receptor Signaling in Response to Peptides and Allosteric Modulators
Kathleen M. Caron, University of North Carolina, Chapel Hill, USA
Role of RAMPs in Disease
Jean-Pierre Vilardaga, University of Pittsburgh, USA
Non-Canonical GPCR Signaling
Short Talk(s) Chosen from Abstracts

PM Plenary: New Insights into GPCR Signaling
Arthur Christopoulos, Monash University, Australia
Orthosteric and Allosteric Ligand Biased Signaling
Vsevolod V. Gurevich, Vanderbilt University, USA
Arrestin Shape-Shifting and Design of Signaling-Biased Mutants
John J.G. Tesmer, University of Michigan, USA
Role of GRKs in Receptor Signaling and Disease
Short Talk Chosen from Abstracts

Poster Session 2

Wednesday, April 2
AM Plenary: Activation of GPCRs and G Proteins
Mark von Zastrow, University of California, San Francisco, USA
GPCR Signaling from Endosomes
Andrew B. Tobin, University of Leicester, UK
In vivo Activation of Receptors Using Phospho-Specific Antibodies
Christopher G. Tate, MRC Laboratory of Molecular Biology, UK
Structural Determinants of Ligand Specificity and Efficacy
Roger K. Sunahara, University of Michigan Medical School, USA
The Mechanism of G Protein Activation through Interactions with GPCRs
Short Talk(s) Chosen from Abstracts

PM Plenary: Targeting GPCRs in Cancer and Inflammation
Xavier J. Leroy, Actelion Pharmaceuticals Ltd, Switzerland
FPR2 Agonists in Inflammatory Disease
Michael Hanson, Receptos Inc., USA
Structure-Based Analysis of S1P1 Receptor Agonists
Suzie Chen, School of Pharmacy, Rutgers University, USA
Metabotropic Glutamate Receptor Signaling in Cancer
Short Talk Chosen from Abstracts

Poster Session 3

Thursday, April 3
AM Plenary: Targeting GPCRs Involved in the Treatment of Diseases of the Central Nervous System
Brigitte L. Kieffer, Institut de Génétique et de Biologie Moléculaire et Cellulaire, France
In vivo Signaling of Opioid Receptors
Sebastien Granier, Institut de Génomique Fonctionnelle, France
Structural Diversity in Opioid Receptors
Fiona H. Marshall, Heptares Therapeutics Ltd., UK
Structure-Based Drug Discovery Applied to CNS GPCRs
Bryan Roth, University of North Carolina, Chapel Hill, USA
GPCR Chemical and Synthetic Biology: New Approaches for CNS Therapeutics
Short Talk(s) Chosen from Abstracts

PM Plenary: Structure and Dynamics of GPCRs
Reinhard Grisshammer, NINDS, National Institutes of Health, USA
Structure of the Agonist-Bound Neurotensin Receptor NTS1
Thomas P. Sakmar, Rockefeller University, USA
Probing Chemokine Receptor Activation Using Genetically-Encoded Unnatural Amino Acids

Closing Keynote Address (Joint)
Brian K. Kobilka, Stanford University School of Medicine, USA
Beta 2 Receptor Conformational Changes

Friday, April 4

30 Mar - 4 Apr 2014
United States of America
meeting website